Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) in a note issued to investors on Thursday. The firm set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw’s price objective suggests a potential upside of 144.44% from the company’s previous close.
A number of other brokerages also recently issued reports on ZNTL. Wall Street Zen raised Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Guggenheim upped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Finally, Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.75.
View Our Latest Research Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Price Performance
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, equities research analysts expect that Zentalis Pharmaceuticals will post -1.83 EPS for the current year.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its position in shares of Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares during the last quarter. Millennium Management LLC boosted its stake in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares during the period. Qube Research & Technologies Ltd purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $37,000. Sei Investments Co. increased its position in shares of Zentalis Pharmaceuticals by 373.1% during the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after acquiring an additional 131,780 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Zentalis Pharmaceuticals by 346.3% during the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after acquiring an additional 515,257 shares during the last quarter.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Featured Articles
- Five stocks we like better than Zentalis Pharmaceuticals
- Rocket Lab Has Corrected Nearly 50%. Is It Still Too Expensive?
- Cybersecurity ETFs Are Rallying While AI Stocks Cool Off
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
